HRCM
CYTK icon

Hood River Capital Management’s Cytokinetics CYTK Stock Holding History

Hood River Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,597
Closed -$8.74M – 175
2025
Q4 		$8.74M Buy
+137,597
New +$8.56M 0.1% 129
2025
Q2 		– Sell
-1,256,580
Closed -$50.5M – 157
2025
Q1 		$50.5M Buy
1,256,580
+267,332
+27% +$12.3M 0.86% 50
2024
Q4 		$46.5M Sell
989,248
-1,548
-0.2% -$80.4K 0.69% 59
2024
Q3 		$52.3M Buy
990,796
+253,159
+34% +$14.1M 0.84% 47
2024
Q2 		$40M Buy
737,637
+40,990
+6% +$2.47M 0.83% 48
2024
Q1 		$48.8M Buy
696,647
+135,666
+24% +$10.5M 1.09% 30
2023
Q4 		$46.8M Buy
560,981
+58,455
+12% +$2.12M 1.29% 29
2023
Q3 		$14.8M Sell
502,526
-1
-0% -$33 0.48% 73
2023
Q2 		$16.4M Buy
502,527
+16,255
+3% +$601K 0.49% 71
2023
Q1 		$17.1M Buy
486,272
+10,799
+2% +$441K 0.55% 62
2022
Q4 		$21.8M Sell
475,473
-394,479
-45% -$17M 0.79% 51
2022
Q3 		$42.1M Buy
869,952
+18,047
+2% +$869K 1.61% 19
2022
Q2 		$33.5M Buy
851,905
+46,331
+6% +$1.87M 1.33% 25
2022
Q1 		$29.7M Buy
805,574
+185,910
+30% +$6.61M 0.99% 38
2021
Q4 		$28.2M Sell
619,664
-3,992
-0.6% -$154K 0.85% 45
2021
Q3 		$22.3M Buy
+623,656
New +$18.4M 0.69% 53

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hood River Capital Management's CYTK Position: Q1 2026 in Review

Hood River Capital Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 137,597 shares — an estimated $8.74M sold.

Hood River Capital Management first reported a position in CYTK in Q3 2021 and held it in 16 quarters. The position peaked at $52.3M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Hood River Capital Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Hood River Capital Management sold 137,597 Cytokinetics shares in Q1 2026, an estimated $8.74M.
  • Hood River Capital Management first reported a position in Cytokinetics in Q3 2021 and held it in 16 quarters.
  • Hood River Capital Management's Cytokinetics position peaked at $52.3M in Q3 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.